Drug firm Jubilant Life Sciences today said its subsidiary Jubilant Pharma has raised USD 300 million (approx Rs 1,998 crore) through issuance of five-year bonds to mainly retire debts.
"Our material wholly-owned subsidiary, Jubilant Pharma Ltd (JPL), has successfully completed the pricing of its rated unsecured high yield bonds (Notes) at a yield of 4.875 per cent per annum issued at par for USD 300 million maturing in September 2021," Jubilant Life Sciences said in a BSE filing.
It further said: "The net proceeds of the Notes shall be used to prepay the existing debt of JPL and its subsidiaries, for upstreaming up to USD 50 million to Jubilant Life Sciences for prepayment of its existing debts and general corporate purposes." Shares of Jubilant Life Sciences were trading 1.89 percent higher at Rs 601 on BSE.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
